Thrombocytopenia in Young Patient due to Anti Tuberculosis Drugs : A Case Report
Downloads
Background: Most anti-tuberculosis (ATD) drugs are relatively safe, but unusual serious reactions can occur. Thrombocytopenia is an uncommon but potentially life-threatening complication of certain ATDs and is characterized by rapid destruction of platelets whenever an offending drug is taken by a susceptible person. Rifampicin is the most common cause of thrombocytopenia.
Case: A 25 years old woman came with chief complaints, shortness of breath since 1 week before admission and cough with phlegm since 2 months before admission. The patient received antibiotic and ATD. In the course of improving on sepsis and pneumonia, the patient had thrombocytopenia accompanied by melena on day 4 of treatment.
Discussion: Thrombocytopenia is defined as a disorder, which showed an abnormality on the low amount of thrombocyte. Thrombocytopenia was commonly cofounded when Complete blood count (CBC) was performed. The majority of the mechanism associated with thrombocytopenia is the immune. Drug-induced Thrombocytopenia (DITP) is an exclusion diagnosis, which is obtained by ruling out other underlying causes that resulted in thrombocytopenia.
Conclusion: This case illustrates that the discovery of isolated thrombocytopenia in a patient taking several medications presents a challenging clinical problem. Laboratory confirmation of drug-induced thrombocytopenia at the time of initial presentation is not possible because tests for drug-dependent anti-platelet antibodies are not available in most clinical laboratories. The diagnosis of drug-induced thrombocytopenia can be supported only by resolution of thrombocytopenia after discontinuation of therapy with the suspected drug.
Efferen LS. Tuberculosis and Pregnancy. Current Opinion in Pulmonary Medicine. 2007; 13: 205-11.
Verma AK, Singh A, Chandra A, Kumar S and Gupta RK. Rifampicin-Induced Thrombocytopenia. Indian J Pharmacol. 2010; 42: 240-2.
Garg R, Gupta V, Mehra S, Singh R and Prasad R. Rifampicin Induced Thrombocytopenia. The Indian Journal Of Tuberculosis. 2007; 54: 94-6.
Braun RLGMM. Thrombocytopenia. American Family Physician. 2012; 85: 612-22.
Pereira J, Hidalgo P, Ocqueteau M, et al. Glycoprotein Ib/IX Complex is the Target in Rifampicin-Induced Immune Thrombocytopenia. British Journal of Haematology. 2000; 110: 907-10.
Visentin GP and Liu CY. Drug-Induced Thrombocytopenia. Hematology/Oncology Clinics. 2007; 21: 685-96.
Aster RH and Bougie DW. Drug-Induced Immune Thrombocytopenia. The New England Journal of Medicine. 2007; 357: 580-7.
Kolyva ASK, Petros C. Old and New TB Drugs: Mechanisms of Action and Resistance. INTECH Open Access Publisher. 2012.
Chong BH, Choi PY, Khachigian L and Perdomo J. Drug-Induced Immune Thrombocytopenia. Hematology/Oncology Clinics of North America. 2013; 27: 521-40.
Kassa E, Enawgaw B, Gelaw A and Gelaw B. Effect of Anti-Tuberculosis Drugs on Hematological Profiles of Tuberculosis Patients Attending at University of Gondar Hospital, Northwest Ethiopia. BMC Hematology. 2016; 16: 1.
Burgess JK, Lopez JA, Gaudry LE and Chong BH. Rifampicin-Dependent Antibodies Bind a Similar or Identical Epitope to Glycoprotein IX-Specific Quinine-Dependent Antibodies. Blood. 2000; 95: 1988-92.
Sun P, Wu G, Gao RL, Liu S, Phillips WD and Liang SX. Rifampicin-Dependent Antibodies Target Glycoprotein IIb/IIIa and Cause Clearance of Human Platelets in NOD/SCID Mice. British Journal of Haematology. 2016; 172: 137-40.
Bansal R, Sharma PK and Sharma A. A Case of Thrombocytopenia Caused by Rifampicin and Pyrazinamide. Indian J Pharmacol. 2013; 45: 405-7.
Banu Rekha V, Adhilakshmi A and Jawahar M. Rifampicin-Induced Acute Thrombocytopenia. Lung India. 2005; 22: 122-4.
Management of Immune-Mediated Thrombocytopenia. Rossi's Principles of Transfusion Medicine. P. 245-64.
Van den Bemt PMLA, Meyboom RHB and Egberts ACG. Drug-Induced Immune Thrombocytopenia. Drug Safety. 2004; 27: 1243-52.
Wazny LD and Ariano RE. Evaluation and Management of Drug-Induced Thrombocytopenia in the Acutely Ill Patient. Pharmacotherapy. 2000; 20: 292-307.
Indonesia KKR. Pedoman Nasional Pengendalian Tuberkulosis. Jakarta: Kementerian Kesehatan Republik Indonesia, 2014.
Marra F, Marra CA, Bruchet N, et al. Adverse Drug Reactions Associated with First-Line Anti-Tuberculosis Drug Regimens. The International Journal of Tuberculosis and Lung Disease : The Official Journal of the International Union against Tuberculosis and Lung Disease. 2007; 11: 868-75.
Thong BY-H, Chia FL-A, Tan S-C, et al. A Retrospective Study on Sequential Desensitization-Rechallenge for Antituberculosis Drug Allergy. Asia Pac Allergy. 2014; 4: 156-63.
1. The journal allows the author to hold the copyright of the article without restrictions.
2. The journal allows the author(s) to retain publishing rights without restrictions.
3. The legal formal aspect of journal publication accessibility refers to Creative Commons Attribution Share-Alike (CC BY-SA).
4. The Creative Commons Attribution Share-Alike (CC BY-SA) license allows re-distribution and re-use of a licensed work on the conditions that the creator is appropriately credited and that any derivative work is made available under "the same, similar or a compatible license”. Other than the conditions mentioned above, the editorial board is not responsible for copyright violation.
JR (